Hoyos says second and third generation GLP-1s could reshape obesity care, while asking whether they'll prove more effective with fewer side effects.
Recap by typeshit. Post by @alfredohoyosmd on Instagram.
The digital health doctor shares a take on GLP-1 therapy paired with lifestyle change and digital programs, calling the finding unsurprising.
Novo Nordisk shared the figure from a post-trial analysis of its next-generation experimental drug, with results broken out for women.
Patients moved off weekly Wegovy injections onto a daily pill, and Men's Journal reports one group's weight outcomes stood out from the rest.
A Facebook post says US researchers found pancreatic cells producing GLP-1 on their own. It frames this as a possible built-in appetite and sugar control system, without naming the study.
10:40
A clinic channel's short take on what tirzepatide does inside the body. No description came with it, so expect a general overview rather than new findings.
About 180 people will get brain scans while choosing between food and money, to see if GLP-1 use dulls the pull of instant rewards.
Loading…